Title
Associations of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use with Colorectal Cancer Risk in the Women's Health Initiative.

Permalink
https://escholarship.org/uc/item/0rc8j5xp

Authors
Brasky, Theodore M
Flores, Katrina F
Larson, Joseph C
et al.

Publication Date
2021-02-24

DOI
10.1158/1055-9965.epi-20-1401

License
https://creativecommons.org/licenses/by/4.0/ 4.0

Peer reviewed
NULL RESULTS IN BRIEF

Associations of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with colorectal cancer risk in the Women’s Health Initiative

Theodore M. Brasky¹, Katrina F. Flores²*, Joseph C. Larson³, Alison M. Newton¹, Aladdin H. Shadyab⁴, Jonathan H. Watanabe⁵, Dorothy S. Lane⁶, Cynthia A. Thomson⁶, Andrea Z. LaCroix²

* Equal contribution

¹ Division of Medical Oncology, The Ohio State University College of Medicine; Columbus, OH
² Division of Epidemiology, Herbert Wertheim School of Public Health and Human Longevity Science, University of California; San Diego, CA
³ Women’s Health Initiative, Fred Hutchinson Cancer Research Center; Seattle, WA
⁴ Department of Clinical Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University of California Irvine; Irvine, CA
⁵ Department of Family, Population and Preventive Medicine, Renaissance School of Medicine at Stony Brook University; Stony Brook, NY
⁶ The University of Arizona Cancer Center; Tucson, AZ

Correspondence:
Theodore M. Brasky
The Ohio State University – James Comprehensive Cancer Center
Tzagournis Research Facility, Suite 514B
420 W. 12th Ave.
Columbus, OH 43210
Phone: 614-293-3772
Email: Theodore.Brasky@osumc.edu

Running Title: Associations of ACEi and ARB with CRC risk

Conflicts of Interest: The authors declare no conflicts of interest

Abbreviations list:
ACEi, angiotensin-converting enzyme inhibitors; AHM, antihypertensive medications; ARB, angiotensin receptor blockers; CI, confidence interval; CT, clinical trials; HR, hazard ratio; OS, observational study; WHI, Women’s Health Initiative.
Abstract

Background: Use of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) has been postulated to reduce cancer risk by inhibition of tumor progression, vascularization, and metastasis. The renin-angiotensin system is upregulated in colorectal cancers; however, the association of ACEi and ARB use with colorectal cancer risk is not well understood.

Methods: The study population was 142,812 Women's Health Initiative participants free of colorectal cancer who reported on ACEi and ARB use at baseline; 2,216 incident colorectal cancers were diagnosed during 10 years of follow-up. Cox regression models estimated adjusted hazard ratios (HR) and 95% confidence intervals (CI) for associations relative to non-use among normotensive women, untreated hypertensive women, and hypertensive women treated with other antihypertensive medications.

Results: HRs among women who used any ACEi or ARB compared to non-use in the 3 referent groups ranged between 0.97 and 1.01. Findings were similar for increased ACEi/ARB duration and for medications examined as separate classes or individually.

Conclusions: In this large prospective study of women, no associations of ACEi or ARB use with colorectal cancer risk were observed.

Impact: Choice of drug in the large population of aging women who will be prescribed ACEi and ARB should be made without factoring in any benefit on colorectal cancer risk.
Introduction

Use of antihypertensive medications (AHM) has increased in the US, with use among women consistently higher than that of men and angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) among the most commonly used medications (1).

Recent studies have suggested that renin-angiotensin system inhibitors—which include ACEi and ARB—may modify cancer risk via inhibition of tumor progression, vascularization, and metastasis (2). Importantly, angiotensin ii has been shown to stimulate mitogenesis in intestinal epithelial cells (3). Additionally, the renin-angiotensin system is upregulated in colorectal cancers (2), and data from experimental animal studies suggest that administration of ACEi or ARB may reduce colon tumorigenesis (4). Several epidemiologic studies have examined associations between use of ACEi or ARB and colorectal cancer risk (4-6), with mixed findings. However, prior studies have been plagued by limitations. Case-control studies have included normotensives or untreated hypertensives in their referent groups, and prospective studies—limited to record linkage analyses—had limited capacity to adjust for confounding factors. Few investigations have examined ACEi and ARB as separate classes and none has examined associations for individual medications within each class, nor estimated risks contrasted against several relevant comparison groups.

We comprehensively examined the association of ACEi and ARB use, separately and combined, with colorectal cancer risk leveraging robust data from the Women’s Health Initiative (WHI), a large cohort of postmenopausal women.

Materials and Methods

Information about the WHI methods have been published previously (7). Between 1993 and 1998, 161,808 postmenopausal women, ages 50 to 79 years, were recruited into a set of four overlapping clinical trials (CT) or an observational study (OS). Women were recruited
directly into the OS, and participation was offered to women who were screened for participation in the CT but were subsequently ineligible or unwilling to participate. After the original WHI study ended in 2005, participants were invited to continue participation in 3 subsequent extension studies, which continued follow-up through 2020. Here, we excluded at baseline women with: prevalent (or missing) colorectal cancer (n=1,075), indeterminate hypertension status (n=3,643), no follow-up time (n=651), and women missing baseline adjustment data (n=13,627), leaving 142,812 women for analysis.

Incident, primary colorectal cancers were reported by questionnaire and confirmed by physician-adjudicators after medical record review. After a median follow-up of 10.0 years, 2,185 colorectal cancers were confirmed. Normotensive and untreated hypertensive women at baseline who self-reported starting antihypertensive therapy during follow-up were right-censored at the date of follow-up when this information was obtained. Participants were additionally censored from the analysis at the earliest date of the following occurrences: withdrawal from the study; death; loss of contact; end of the original follow-up (for participants not enrolled in the WHI extension studies); end of the extension studies; or March 1, 2019, the last available date of the WHI extension study outcome adjudication.

Women attended baseline screening visits and completed extensive baseline questionnaires. Height, weight, and blood pressure (see (8)) were measured by trained clinical staff. We defined untreated hypertension as no AHM use at baseline and either self-reported treatment of hypertension prior to baseline, or systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg at baseline. Women using AHM at baseline were considered to have treated hypertension, whereas women who did not meet these criteria and who were not using AHM were classified as normotensive. In-person medication inventories were obtained by review of participants’ pill containers. This database classified brand and generic names, national drug codes and therapeutic class codes. Information was collected on duration of
current prescription medications by self-report; however, no information was collected on medications that had been discontinued prior to baseline.

In this study, use of ACEi and ARB was defined as any current use of an ACEi or ARB, including monotherapy and polytherapy with other anti-hypertensive medications. Separate variables were additionally created for ACEi and ARB use, and duration of their use was categorized as <1 year, 1-4.9 years, and ≥5 years (ACEi only). Due to their introduction to the US market in 1995, baseline data for ARB were restricted to participants who were recruited between 1995 and 1998 and duration of use was restricted to <5 years.

**Statistical analysis**

To address the potential for hypertension to be an underlying contributor to colorectal cancer risk, and the potential for untreated hypertension to confound associations, we examined associations between ACEi/ARB use (n=13,078) and colorectal cancer risk compared to non-use in 3 comparison groups: 1) normotensive women (n=78,108); 2) untreated hypertensives women (n=20,286); and, 3) hypertensive women treated with any other AHM (n=31,340). Cox proportional hazards regression estimated associations between ACEi/ARB use and colorectal cancer risk relative to non-use among referent categories. Models were adjusted *a priori* for colorectal cancer risk factors and correlates of hypertension/AHM use.

**Results**

Baseline characteristics of WHI participants, stratified on hypertension and treatment status, are given in **Supplemental Table S1**. Differences between hypertensive and normotensive women tended to be small. Untreated hypertensive women and hypertensive women treated with other AHM were generally similar with respect to their baseline characteristics.
Use of ACEi or ARB was not associated with colorectal cancer risk compared to non-use among normotensives, untreated hypertensives, and hypertensives treated with other AHM medications (Table 1). Increased duration of any ACEi or ARB use or consideration of ACEi or ARB use as separate classes was also not associated with colorectal cancer risk. In a secondary analysis limited by use frequencies and low case numbers, associations for individual medications as well as mono- and polytherapy were generally similar to those observed for ACEi and ARB classes (Table 2).

Discussion

In this prospective cohort study of postmenopausal women, we found no association of ACEi or ARB use with colorectal cancer risk when compared to normotensive women and treated or untreated hypertensive women.

Several prior studies, including case-control and prospective record linkage studies have examined ACEi/ARB and colorectal cancer risk (4-6). Similar to our findings, neither case-control study reported a clear association between ACEi or ARB and colorectal cancer (4,6). Our findings further agree with 3 prior record linkage studies (4,5). Most recently, Htoo et al. (5), examined combined ACEi/ARB use among US Medicare beneficiaries, and reported no association. In contrast, 3 prospective studies, including 2 from the same UK database, reported significant inverse associations for ACEi or ARB (4). The discrepancy between these findings may be due to confounding given these prior studies' limited ability to control for CRC risk factors and the inclusion of untreated hypertensives in the comparison group.

This study has several strengths, including its prospective design, long follow-up, physician confirmation of outcomes, robust consideration of potential confounders, and careful measurement of medication use. It is the first to examine associations for individual medications within ACEi and ARB classes. The study was limited in statistical power by stratifying referent groups, and lacked data on medications discontinued prior to baseline.
This study adds to a growing body of evidence that the use of ACEi and ARB for hypertension control in post-menopausal women is not associated with colorectal cancer risk. These findings suggest that choice of drug in the large population of aging women who will be prescribed AHM should be made without factoring in any benefit on risk of colorectal cancer.
Acknowledgements

Funding: This work is supported by the National Heart, Lung, and Blood Institute, National Institutes of Health and U.S. Department of Health and Human Services grants HHSN2682011000046C, HHSN268201100001C, HHSN268201100002C, HHSN268201100003C, and HHSN268201100004C. The funding source had no role in the collection of data, the analysis, interpretation, or writing of this report, or the decision to submit the article for publication.

A short list of Women’s Health Initiative Investigators:

Program Office: (National Heart, Lung, and Blood Institute, Bethesda, Maryland) Jacques Rossouw, Shari Ludlam, Joan McGowan, Leslie Ford, and Nancy Geller

Clinical Coordinating Center: (Fred Hutchinson Cancer Research Center, Seattle, WA) Garnet Anderson, Ross Prentice, Andrea LaCroix, and Charles Kooperberg

Investigators and Academic Centers: (Brigham and Women’s Hospital, Harvard Medical School, Boston, MA) JoAnn E. Manson; (MedStar Health Research Institute/Howard University, Washington, DC) Barbara V. Howard; (Stanford Prevention Research Center, Stanford, CA) Marcia L. Stefanick; (The Ohio State University, Columbus, OH) Rebecca Jackson; (University of Arizona, Tucson/Phoenix, AZ) Cynthia A. Thomson; (University at Buffalo, Buffalo, NY) Jean Wactawski-Wende; (University of Florida, Gainesville/Jacksonville, FL) Marian Limacher; (University of Iowa, Iowa City/Davenport, IA) Jennifer Robinson; (University of Pittsburgh, Pittsburgh, PA) Lewis Kuller; (Wake Forest University School of Medicine, Winston-Salem, NC) Sally Shumaker; (University of Nevada, Reno, NV) Robert Brunner

Women’s Health Initiative Memory Study: (Wake Forest University School of Medicine, Winston-Salem, NC) Mark Espeland
References

1. Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010. Circulation 2012;126(17):2105-14 doi 10.1161/circulationaha.112.096156.

2. George AJ, Thomas WG, Hannan RD. The renin-angiotensin system and cancer: old dog, new tricks. Nature reviews Cancer 2010;10(11):745-59 doi 10.1038/nrc2945.

3. Chiu T, Santiskulvong C, Rozengurt E. ANG II stimulates PKC-dependent ERK activation, DNA synthesis, and cell division in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2003;285(1):G1-11 doi 10.1152/ajpgi.00419.2002.

4. Dai YN, Wang JH, Zhu JZ, Lin JQ, Yu CH, Li YM. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy and colorectal cancer: a systematic review and meta-analysis. Cancer Causes Control 2015;26(9):1245-55 doi 10.1007/s10552-015-0617-1.

5. Htoo PT, Sturmer T, Jonsson-Funk M, Pate V, Simpson RJ, Jr., Lund JL. Renin-Angiotensin-Aldosterone System-based Antihypertensive Agents and the Risk of Colorectal Cancer Among Medicare Beneficiaries. Epidemiology 2019;30(6):867-75 doi 10.1097/ede.0000000000001065.

6. Dierssen-Sotos T, Gómez-Acebo I, Palazuelos C, Rodriguez-Moranta F, Pérez-Gómez B, Fernández Vazquez JP, et al. Relationship between drugs affecting the renin-angiotensin system and colorectal cancer: The MCC-Spain study. Preventive medicine 2017;99:178-84 doi 10.1016/j.ypmed.2017.01.011.

7. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Controlled clinical trials 1998;19(1):61-109.

8. Anderson GL, Manson J, Wallace R, Lund B, Hall D, Davis S, et al. Implementation of the Women's Health Initiative study design. Annals of epidemiology 2003;13(9 Suppl):S5-17.
Table 1. Associations of ACEi and ARB with colorectal cancer risk relative to non-use among normotensive women, untreated hypertensive women, and hypertensive women treated with other antihypertensive medications in the Women’s Health Initiative (n=142,812).

| Reference Population | Normotensive women (n=78,108, n cases=1,051) | Untreated hypertensive women (n=20,286, n cases=171) | Hypertensive women treated with any other AHM (n=31,340, n cases=688) |
|----------------------|---------------------------------------------|---------------------------------------------|-------------------------------------------------|
|                      | n cases                                     | Model 1† HR (95% CI) | Model 2‡ HR (95% CI) | Model 1† HR (95% CI) | Model 2‡ HR (95% CI) | Model 1† HR (95% CI) | Model 2‡ HR (95% CI) |
| Any ACEi/ARB Duration of use (years) | 275 | 1.05 (0.92, 1.21) | 1.00 (0.87, 1.16) | 1.03 (0.85, 1.25) | 1.01 (0.83, 1.23) | 1.00 (0.87, 1.15) | 0.97 (0.85, 1.12) |
| <1                   | 74  | 1.20 (0.95, 1.52) | 1.14 (0.90, 1.45) | 1.17 (0.89, 1.54) | 1.15 (0.87, 1.52) | 1.14 (0.90, 1.45) | 1.11 (0.87, 1.41) |
| 1-4.9                | 112 | 0.93 (0.77, 1.14) | 0.89 (0.73, 1.09) | 0.91 (0.72, 1.16) | 0.90 (0.70, 1.14) | 0.89 (0.73, 1.09) | 0.86 (0.71, 1.05) |
| ≥5                   | 89  | 1.12 (0.90, 1.39) | 1.07 (0.85, 1.33) | 1.09 (0.84, 1.41) | 1.08 (0.83, 1.39) | 1.06 (0.85, 1.33) | 1.03 (0.83, 1.29) |
| Any ACEi use Duration of use (years) | 254 | 1.06 (0.93, 1.22) | 1.01 (0.88, 1.17) | 1.04 (0.85, 1.26) | 1.02 (0.84, 1.24) | 1.01 (0.88, 1.17) | 0.98 (0.85, 1.13) |
| <1                   | 61  | 1.21 (0.94, 1.57) | 1.15 (0.88, 1.49) | 1.18 (0.88, 1.59) | 1.16 (0.86, 1.56) | 1.15 (0.89, 1.50) | 1.11 (0.86, 1.45) |
| 1-4.9                | 104 | 0.95 (0.77, 1.16) | 0.90 (0.73, 1.10) | 0.92 (0.72, 1.18) | 0.91 (0.71, 1.16) | 0.90 (0.73, 1.11) | 0.87 (0.71, 1.07) |
| ≥5                   | 89  | 1.13 (0.91, 1.41) | 1.08 (0.87, 1.35) | 1.11 (0.86, 1.43) | 1.09 (0.84, 1.41) | 1.08 (0.86, 1.34) | 1.05 (0.84, 1.31) |
| Any ARB use Duration of use (years) | 21  | 0.93 (0.60, 1.43) | 0.91 (0.59, 1.41) | 0.90 (0.57, 1.43) | 0.92 (0.58, 1.45) | 0.88 (0.57, 1.36) | 0.88 (0.57, 1.36) |
| <1                   | 13  | 1.11 (0.64, 1.92) | 1.10 (0.63, 1.90) | 1.08 (0.62, 1.91) | 1.11 (0.63, 1.95) | 1.05 (0.61, 1.83) | 1.06 (0.61, 1.84) |
| 1-4.9                | 8   | 0.81 (0.40, 1.62) | 0.79 (0.39, 1.59) | 0.79 (0.39, 1.60) | 0.80 (0.39, 1.62) | 0.77 (0.38, 1.54) | 0.77 (0.38, 1.54) |

Baseline hazards are stratified on hysterectomy status, WHI Dietary Modification Trial arm (intervention, comparison, not randomized), study component (clinical trial, observational study), and WHI follow-up period (original study period, extension 1, extension 2, extension 3)
† Adjusted for age, race/ethnicity, and education
‡ Adjusted for age, race/ethnicity, education, diabetes, coronary heart disease, inflammatory bowel disease, colorectal cancer screening, family history of colorectal cancer, duration of estrogen-only hormone therapy, duration of combined hormone therapy, body mass index, physical activity, smoking, alcohol, non-steroidal anti-inflammatory drug use, and red/processed meat intake.
Abbreviations: ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; AHM, antihypertensive medications
Table 2. Associations of individual ACEi/ARB medications, monotherapy, and polytherapy with colorectal cancer risk in the Women's Health Initiative (n=142,812).

| Reference Population | Normotensive women (n=78,108, n\_cases=1,051) | Untreated hypertensive women (n=20,286, n\_cases=171) | Hypertensive women treated with any other AHM (n=31,340, n\_cases=688) |
|----------------------|---------------------------------------------|-------------------------------------------------|-------------------------------------------------|
|                      | Model 1† HR (95% CI) | Model 2‡ HR (95% CI) | Model 1† HR (95% CI) | Model 2‡ HR (95% CI) | Model 1† HR (95% CI) | Model 2‡ HR (95% CI) |
| ACEi§                | n\_cases | | | | | |
| Benazepril           | 23      | 0.98 (0.65, 1.48) | 0.93 (0.61, 1.41) | 0.95 (0.62, 1.48) | 0.94 (0.61, 1.45) | 0.93 (0.61, 1.41) | 0.90 (0.59, 1.37) |
| Captopril            | 16      | 0.97 (0.59, 1.59) | 0.87 (0.53, 1.43) | 0.95 (0.57, 1.58) | 0.88 (0.52, 1.47) | 0.92 (0.56, 1.52) | 0.84 (0.51, 1.38) |
| Enalapril            | 67      | 1.11 (0.86, 1.42) | 1.05 (0.81, 1.35) | 1.08 (0.81, 1.44) | 1.05 (0.79, 1.40) | 1.05 (0.82, 1.35) | 1.01 (0.79, 1.30) |
| Fosinopril           | 15      | 1.23 (0.74, 2.05) | 1.15 (0.69, 1.92) | 1.20 (0.71, 2.04) | 1.16 (0.68, 1.97) | 1.17 (0.70, 1.95) | 1.11 (0.67, 1.86) |
| Lisinopril           | 98      | 1.00 (0.81, 1.23) | 0.97 (0.79, 1.20) | 0.98 (0.76, 1.26) | 0.98 (0.76, 1.26) | 0.95 (0.77, 1.18) | 0.94 (0.76, 1.16) |
| Quinapril            | 21      | 1.08 (0.70, 1.66) | 1.02 (0.66, 1.58) | 1.05 (0.67, 1.66) | 1.03 (0.65, 1.63) | 1.03 (0.66, 1.58) | 0.99 (0.64, 1.53) |
| Ramipril             | 12      | 1.74 (0.99, 3.08) | 1.60 (0.91, 2.84) | 1.70 (0.95, 3.06) | 1.62 (0.90, 2.91) | 1.66 (0.94, 2.93) | 1.55 (0.88, 2.75) |
| ARB§                 |          | | | | | |
| Losartan             | 21      | 1.03 (0.67, 1.59) | 1.01 (0.65, 1.56) | 1.01 (0.64, 1.59) | 1.02 (0.65, 1.61) | 0.98 (0.63, 1.51) | 0.98 (0.63, 1.51) |
| Monotherapy          |          | | | | | |
| Any ACEi/ARB Use     | 121     | 1.01 (0.83, 1.22) | 0.97 (0.80, 1.17) | 0.98 (0.78, 1.24) | 0.97 (0.77, 1.23) | 0.96 (0.79, 1.16) | 0.93 (0.77, 1.14) |
| Polytherapy – ACEi/ARB use plus: | | | | | | |
| Beta blockers        | 9       | 0.69 (0.36, 1.34) | 0.69 (0.35, 1.32) | 0.68 (0.35, 1.33) | 0.69 (0.35, 1.35) | 0.66 (0.34, 1.27) | 0.66 (0.34, 1.28) |
| Calcium channel blockers | 29     | 1.28 (0.89, 1.86) | 1.23 (0.84, 1.78) | 1.25 (0.84, 1.86) | 1.24 (0.83, 1.84) | 1.22 (0.84, 1.77) | 1.19 (0.82, 1.72) |
| Diuretics            | 78      | 1.20 (0.95, 1.51) | 1.14 (0.90, 1.44) | 1.17 (0.90, 1.54) | 1.15 (0.87, 1.50) | 1.14 (0.90, 1.44) | 1.10 (0.87, 1.39) |
| Multiple antihypertensive medication classes | 38   | 1.01 (0.73, 1.40) | 0.95 (0.68, 1.32) | 0.98 (0.69, 1.40) | 0.96 (0.67, 1.37) | 0.96 (0.69, 1.33) | 0.92 (0.66, 1.28) |

Baseline hazards are stratified on hysterectomy status, WHI Dietary Modification Trial arm (intervention, comparison, not randomized), study component (clinical trial, observational study), and WHI follow-up period (original study period, extension 1, extension 2, extension 3)
† Adjusted for age, race/ethnicity, and education
‡ Adjusted for age, race/ethnicity, education, diabetes, coronary heart disease, inflammatory bowel disease, colorectal cancer screening, family history of colorectal cancer, duration of estrogen-only hormone therapy, duration of combined hormone therapy, body mass index, physical activity, smoking, alcohol, non-steroidal anti-inflammatory drug use, and red/processed meat intake.
§ Moexipril, Trandolapril, Irbesartan, and Valsartan are excluded from the analysis due to low frequencies.
Abbreviations: ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; AHM, antihypertensive medications
Associations of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with colorectal cancer risk in the Women's Health Initiative

Theodore M. Brasky, Katrina F Flores, Joseph C. Larson, et al.

Cancer Epidemiol Biomarkers Prev  Published OnlineFirst February 24, 2021.

Updated version
Access the most recent version of this article at:
doi:10.1158/1055-9965.EPI-20-1401

Supplementary Material
Access the most recent supplemental material at:
http://cebp.aacrjournals.org/content/suppl/2021/02/12/1055-9965.EPI-20-1401.DC1

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://cebp.aacrjournals.org/content/early/2021/02/24/1055-9965.EPI-20-1401. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.